According to filings with the U.S. Securities and Exchange Commission, StataDx is raising up to $5,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Sidhant Jena played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About StataDx
Stata DX is based on the eRapid technology developed at Harvards Wyss Institute. eRapid is a low-cost, affinity-based electrochemical sensing platform that can simultaneously detect a broad range of biomarkers with high sensitivity and selectivity in complex biological fluids, using as little as a single drop of blood. It features a novel, antifouling nano-composite coating to which probes are attached that are specific to the target biomarker. When the target binds to the probe, it attracts a second probe to create a sandwich that triggers the formation of a local precipitate on the coated electrode surface that is electrically active. The magnitude of the electrical signal generated correlates with the concentration of the target detected in the sample, and because the precipitate forms locally, many different biomarkers can be tested in parallel on the same sample.

To learn more about StataDx, visit http://www.statadx.com/

Contact:
Sidhant Jena, Chief Executive Officer
857-204-5056

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.